Login to Your Account



Clinic Roundup


Wednesday, May 11, 2011
Talon Therapeutics Inc., of San Mateo, Calif., began a Phase III trial of Marqibo (vincristine sulfate liposomes injection) for non-Hodgkin lymphoma. The study will be carried out by the German High-Grade non-Hodgkin lymphoma study group (DSHNHL). The trial will enroll 1,000 patients 61-80 years of age, and patient treatment will begin in the third quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription